In a 5XFAD mouse study, intranasal long R3 IGF-1 changed amyloid-plaque features but did not preserve the measured cognitive outcomes. This is preclinical evidence and does not validate human use or transfer the approval of other IGF-1 medicines to LR3.[1]
- LR3, native IGF-1 and approved mecasermin are not interchangeable evidence identities.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Independent fresh reinspection for the deep-evidence pass: reopened every cited source at its passages via NCBI E-utilities / DailyMed / accessdata.fda.gov / govinfo.gov / Wayback Machine mirror, checked Europe PMC correction/retraction metadata where applicable, and confirmed the claim's wording against the primary text. Disposition: supported within the stated scope. No qualified clinical review.